Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Clorox reports after market close, meaning Day 0 captures anticipatory trading before results are released, while Day +1 reflects the market's first full session to digest the actual numbers.

Historical price behavior shows moderate Day 0 moves averaging 1.37% in absolute terms, with a typical range of 2.28%, reflecting relatively muted anticipation ahead of the release. However, Day +1 moves are significantly larger, averaging 4.09% in absolute terms with a 5.17% range, indicating that the market's reaction to actual results tends to be substantial.

The most recent earnings on August 3, 2026, saw a +2.86% Day 0 move and a +6.52% Day +1 move, the largest one-day reaction in the past eight quarters. In contrast, the April 30, 2026 report produced a -9.67% Day +1 decline, the sharpest negative reaction in the dataset. The February 3, 2025 report also triggered a notable -7.24% Day +1 drop. These swings demonstrate that while Clorox often trades quietly into earnings, post-announcement volatility can be significant, particularly when results or guidance deviate from expectations. Investors should prepare for potential moves in the 4-6% range on Day +1 based on historical patterns.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 7.62% through the November 20 expiration, which is notably higher than the 4.09% average absolute Day +1 move observed historically. This elevated implied volatility suggests options traders are anticipating a larger-than-typical reaction, likely reflecting uncertainty around margin guidance, dividend sustainability, and the Purell integration trajectory.

Part 3: What Analysts Are Saying

Analysts maintain a cautious stance on Clorox heading into earnings, with a consensus rating that translates to Hold. The average price target of $92.12 implies approximately 4.7% upside from the current price of $88.00, suggesting limited near-term conviction despite the modest discount to fair value.

The rating breakdown shows 14 Hold ratings and 4 Strong Sell ratings among 18 analysts, with zero Buy or Strong Buy recommendations. This distribution reflects skepticism about the company's ability to navigate inflation headwinds and restore margin expansion while maintaining its dividend. The average recommendation of 2.56 on the 1-5 scale (where 3 = Hold) leans slightly toward the bearish side of neutral.

Sentiment has remained unchanged over the past month, with the rating distribution and average recommendation holding steady at 2.56. The lack of upgrades or downgrades suggests analysts are in wait-and-see mode ahead of the earnings report, looking for evidence that management's second-half recovery narrative can materialize. The price target range spans from a low of $74.00 to a high of $117.00, reflecting wide disagreement about the stock's trajectory—the high estimate implies 33% upside, while the low suggests 16% downside risk.

The consensus view appears to hinge on execution: if Clorox can demonstrate margin stabilization, free cash flow generation sufficient to cover the dividend, and sustained momentum in the Purell-driven Health and Wellness segment, the Hold ratings could shift more constructive. However, any guidance cut or margin disappointment would likely trigger further downgrades given the already defensive positioning.

Part 4: Technical Picture

Clorox enters earnings with a Sell signal at 80%, reflecting bearish technical momentum that has persisted over recent weeks. The signal stood at 88% Sell both one week ago and one month ago, indicating a slight improvement in the near term but sustained negative pressure overall.

Timeframe Analysis:

• Short-term (50% Sell): Moderate sell signal suggests near-term momentum remains under pressure, though less extreme than medium and long-term readings
• Medium-term (100% Sell): Strong sell signal indicates clear weakness in the intermediate timeframe, with no bullish technical support
• Long-term (100% Sell): Strong sell signal reflects persistent weakness in the longer-term trend, consistent with the stock's 19.39% decline over the past year

Trend Characteristics: The technical environment is characterized by Good strength but Average direction, suggesting that while price movements have been decisive, the overall trend lacks clear directional conviction heading into earnings.

The stock is trading at $88.00, positioned above its 5-day ($87.53), 10-day ($87.05), and 20-day ($85.63) moving averages, indicating short-term stabilization after recent weakness. However, the price remains below its 50-day ($88.60), 100-day ($93.72), and 200-day ($99.77) moving averages, confirming that the longer-term trend remains negative. The stock is testing resistance at the 50-day moving average, a level that has capped rallies in recent months.

The 52-week range of $79.12 to $128.90 shows the stock trading closer to its lows, approximately 11% above the bottom and 32% below the peak. With the stock hovering just below the 50-day moving average and all longer-term trend indicators in sell territory, the technical setup is cautionary heading into earnings. A beat-and-raise scenario would need to be convincing to break through overhead resistance, while any disappointment could send the stock back toward the $79-$81 support zone. The combination of bearish medium and long-term signals, elevated options-implied volatility, and proximity to key moving average resistance suggests limited technical cushion if results or guidance disappoint.